Original Article
Author Details :
Volume : 9, Issue : 1, Year : 2023
Article Page : 7-15
https://doi.org/10.18231/j.ijooo.2023.002
Abstract
Aims: To study the statistics of the epidemiology, co-morbidities, clinical presentations, management and prognosis of the study group.
Materials and Methods: This is a retrospective study conducted in a tertiary care hospital in South India, among 100 subjects, between May 2021 and August 2021 when the Mucor mycosis cases were frequently being diagnosed and treated amongst COVID-19 infected patients.
The results showed that 34.0% were between 51-60 years with 100% patients confirmed COVID positive through RTPCR tests. 86.0% had confirmed mucor on CT scan. 50.0% had both eyes vision of 6/60 on presentation. 67.% had periorbital swelling with 51% having prior co-morbidities.63.0% patients received tablet Posaconazole 30mg as medical treatment and 60.0% required no surgical management.10.0% required orbital exenteration and 21.0% required partial maxillectomy.2% experienced orbital apex syndrome as associated complications.97.0% were discharged post treatment with 3% mortality. There was a positive correlation of medical management with respect to anterior segment and posterior segment findings P<0 P=0.79. P=0.43.>
Conclusion: This study shows that immune suppression is directly related to infectivity by mucor mycosis. In order to contain symptomatology and grave prognosis amongst patients, early diagnosis, affordable treatment and follow-up including patient education about the etiology and pathogenesis of the disease must be available.
Keywords: Mucor mycosis, Corona virus, Rhinoorbitocerebral mucor mycosis, Black Fungus, Immune suppression
How to cite : Madhusudhan C N, Raghavendra R, Balakrishna N, Prakash D, Satish K, Clinical presentations, epidemiology and management of COVID-19 associated Mucor mycosis in a tertiary care hospital in South India. IP Int J Ocul Oncol Oculoplasty 2023;9(1):7-15
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Received : 05-04-2023
Accepted : 25-04-2023
Viewed: 577
PDF Downloaded: 171